This study presents a novel perspective on the influences of the microbiome-cancer axis during tumor development and treatment, in a syngeneic, immunocompetent mammary tumor mouse model. The findings define substantial remodeling of the gut microbiome and changes in the intestinal immune network in response to the orally administered therapeutic Hedgehog inhibitor, Vismodegib, and highlight the dynamic shifts in the abundance of pro- and anti-inflammatory gut microbes during tumor progression and in response to Hedgehog blockade.
- Dominique C. Hinshaw
- Courtney A. Swain
- Lalita A. Shevde
